Multiple endocrine neoplasia type 2 historical perspective

	Multiple endocrine neoplasia type 2 Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple endocrine neoplasia type 2 from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications & Prognosis
Diagnosis
Diagnostic Criteria
History & Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Multiple endocrine neoplasia type 2 historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Multiple endocrine neoplasia type 2 historical perspective
CDC on Multiple endocrine neoplasia type 2 historical perspective
Multiple endocrine neoplasia type 2 historical perspective in the news
Blogs on Multiple endocrine neoplasia type 2 historical perspective
Directions to Hospitals Treating Multiple endocrine neoplasia type 2
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

==Historical Perspective==

**MEN II Historical Background**
Years	Scientist	Contribution
1954	Wermer	Reported that syndrome was transmitted as a dominant trait
1959	Hazard	Described medullary (solid) thyroid carcinoma
1961	Sipple	Described a combination of a pheochromocytoma, medullary thyroid carcinoma and parathyroid adenoma
1965	Schimke and Hartmann	Described a syndrome of pheochromocytoma and medullary thyroid carcinoma with abundant amyloid stroma^[1]
1966	Williams	Described the combination of mucosal neuromas, pheochromocytoma and medullary thyroid carcinoma
1968	Steiner	Introduced the term "multiple endocrine neoplasia" (MEN) to describe disorders featuring combinations of endocrine tumors and proposed the terms 'Wermer syndrome' for MEN 1 and 'Sipple syndrome' for MEN 2
1974	Sizemore	Showed that the MEN 2 category included two groups of patients with MTC and pheochromocytoma: one with parathyroid disease and a normal appearance (MEN 2A) and the other without parathyroid disease but with mucosal neuromas and mesodermal abnormalities (MEN 2B)
1993		RET germline mutations were recognized as the causative molecular alterations in MEN 2 syndromes
1998		MEN1 gene was cloned^[2]

↑ Schimke RN, Hartmann WH (1965). "Familial amyloid-producing medullary thyroid carcinoma and pheochromocytoma. A distinct genetic entity". Ann Intern Med. 63 (6): 1027–39. PMID 5844561.
↑ Guru SC, Manickam P, Crabtree JS, Olufemi SE, Agarwal SK, Debelenko LV. Identification and characterization of the multiple endocrine neoplasia type 1 (MEN1) gene. J Intern Med 243(6) 433-9